Summary of BridgeBio's 2026 Conference Call Company Overview - **Company**: BridgeBio (NasdaqGS:BBIO) - **Event**: 2026 Leerink Partners Global Healthcare Conference - **Date**: March 10, 2026 Key Points TTR Market and Attruby Performance - **Patient Growth**: Accelerated from approximately 60 patients per week at launch to over 150 patients per week, indicating strong market acceptance [3][5] - **Market Dynamics**: The growth is attributed to: - Strong clinical data supporting Attruby as the first near-complete stabilizer for TTR [3] - Increased disease awareness and improved diagnosis through AI initiatives [4] - Broader prescriber base, particularly high-volume heart failure clinics [4][5] - **Market Share**: Achieved over 25% share in treatment-naive patients within a year of launch, with a goal of exceeding 30% [5] - **Pricing Stability**: Net pricing for Attruby remains stable, with gross-to-net ratios in the 30%-40% range [6][7] European Market and BEYONTTRA - **Partnership with Bayer**: Successful collaboration for the launch of BEYONTTRA, with over 50% treatment-naive share in Germany due to a single-payer system [9][10] - **Future Launches**: Upcoming launches planned in Denmark, Spain, Italy, and France, with royalties starting at 30% [11] Combination Therapy and Competitive Landscape - **Tafamidis IP Discussion**: Potential outcomes for tafamidis patent litigation could impact market dynamics, with expectations of generic entry possibly in the 2030s [12] - **Combination Therapy Insights**: Current data shows no significant benefits from combination therapies, with a focus on establishing Attruby as the most potent stabilizer [13][14] Pipeline Developments - **Depleter Program**: BridgeBio is developing an in-house depleter to complement Attruby, targeting the removal of monomers that cause cardiomyopathy [15][16][17] - **Achondroplasia Strategy**: Infigratinib is positioned as a superior oral treatment option, with a focus on market expansion through patient switches from injections [18][22][23] - **Global Launch Plans**: International strategy involves a phased approach, starting with Germany, with regulatory filings expected to lag behind U.S. timelines by 3-4 months [27][28] Financial Outlook and Margin Profile - **Cost Management**: R&D expenses are expected to remain flat, while SG&A expenses will increase due to upcoming launches [39] - **Margin Expectations**: Anticipated gross margins for new products could reach 70%-80%, with a significant increase in total operating spend as new products launch [50] Additional Insights - **Equity Stake in GondolaBio**: BridgeBio holds an equity stake in GondolaBio, an early-stage R&D engine, which may be integrated into future strategies [52] This summary encapsulates the critical insights and strategic directions discussed during the conference call, highlighting BridgeBio's growth trajectory, market strategies, and financial outlook.